Balestra et al. (2025) proved that targeting the thymic stromal lymphopoietin receptor (TSLPR) reduced resistance to immunotherapy in CRLF2-rearranged and DS-ALL, offering potential for therapeutic interventions [70]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.